Your shopping cart is currently empty

AURKA-IN-3 (Compound AL8) is an irreversible covalent inhibitor of Aurora kinase A (AURKA) with an IC50 of 23.0 nM. It inhibits the activation of AURKA-mediated cAMP and phospholipase C (PLC) signaling pathways, as well as reduces the autophosphorylation of AURKA. AURKA-IN-3 is a potential candidate for research into malignancies associated with high AURKA expression, such as leukemia and lymphoma.
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | AURKA-IN-3 (Compound AL8) is an irreversible covalent inhibitor of Aurora kinase A (AURKA) with an IC50 of 23.0 nM. It inhibits the activation of AURKA-mediated cAMP and phospholipase C (PLC) signaling pathways, as well as reduces the autophosphorylation of AURKA. AURKA-IN-3 is a potential candidate for research into malignancies associated with high AURKA expression, such as leukemia and lymphoma. |
| Targets&IC50 | Aurora A:23.0 nM |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.